Early Phase 1 Hypertension Trial, Recruiting NCT04832009 Sponsor: University of Kansas Medical Center Condition: Hypertension
Back to Hypertension

Early Phase 1 Hypertension Trial, Recruiting

NCT04832009
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with a BMI (body mass index) under 25, which is generally considered a healthy weight range
  • People whose body processes insulin normally, based on blood test results from fasting glucose and insulin levels
  • People aged between 18 and 79 years old
  • People with blood pressure below 140 (top number) and below 90 mmHg (bottom number)
  • People whose weight has stayed roughly the same (within about 5 pounds) over the past 3 months
  • People who are willing and able to stop taking vitamin C, vitamin E, or omega-3 fatty acid supplements at least 2 weeks before the trial begins
  • People who are willing and able to sign a written consent form agreeing to take part

Who may not be able to join:

  • People who have Type 1 or Type 2 diabetes, or whose fasting blood sugar or HbA1c (a measure of average blood sugar) is above certain levels
  • People who currently smoke or who have smoked in the past 3 months
  • People who have high levels of fats (triglycerides) in their blood, above 250 mg/dL
  • People with high blood pressure above 130/80 mmHg
  • People with a history of heart disease, such as a heart attack, stroke, heart failure, stent placement, valve problems, or heart muscle disease
  • People with a history of vascular (blood vessel) disease, such as bypass surgery or stroke

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Seth W. W Holwerda, PhD, University of Kansas Medical Center

Phone: 9729223230

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
9 May 2022
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Efficacy of Infusion of Ascorbic Acid; Efficacy of Infusion of Ascorbic Acid; Efficacy of Infusion of Ascorbic Acid; Efficacy of Infusion of Ascorbic Acid; Efficacy of Infusion of Ascorbic Acid

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov